New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
Heart failure with reduced ejection fraction (HFrEF) is a public health issue, because some patients, despite using standard treatment, still develop worsening heart failure. The risk of adverse outcomes is especially high in patients who require readmission or emergency care on an outpatient basis....
Saved in:
Main Author: | I. V. Gribkova |
---|---|
Format: | Article |
Language: | English |
Published: |
Столичная издательская компания
2024-03-01
|
Series: | Рациональная фармакотерапия в кардиологии |
Subjects: | |
Online Access: | https://www.rpcardio.online/jour/article/view/2954 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Practical aspects of vericiguat therapy in patients with heart failure with reduced ejection fraction. Expert council resolution
by: S. A. Boytsov, et al.
Published: (2023-05-01) -
Biomarkers in the Pathogenesis of Heart Failure with Preserved as Well as Reduced Ejection Fraction: A Cross-sectional Study
by: Sowmiya Thiyagarajan, et al.
Published: (2025-06-01) -
Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01) -
The Physical Activity in the Management of Heart Failure with Reduced Ejection Fraction A Review of Current Evidence and Recommendations
by: Natalia Smyl, et al.
Published: (2025-07-01) -
Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)